Aims Statin intolerance (SI) represents a significant public health problem for which precise
estimates of prevalence are needed. Statin intolerance remains an important clinical …

Rosuvastatin is a new generation HMG-CoA reductase inhibitor which exhibits some unique
pharmacologic and pharmacokinetic properties. It has low extrahepatic tissue penetration …

The coronavirus disease-2019 (COVID-19) is caused by SARS-CoV-2, leading to acute
respiratory distress syndrome (ARDS), thrombotic complications, and myocardial injury …

HMG-CoA reductase inhibitors (statins) are the mainstay in the pharmacologic management
of dyslipidemia. Since they are widely prescribed, their safety remains an issue of concern …

Rosuvastatin is a fully synthetic statin wich acts by interfering with the endogenous synthesis
of cholesterol through competitively inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A …

Aim We aimed to compare the effects of fixed‐dose combinations of ezetimibe plus
rosuvastatin to rosuvastatin alone in patients with primary hypercholesterolemia, including a …

Objectives Despite recent advances in the understanding of the role of NLRP3
inflammasomes in coronary atherosclerosis, further work on their activation and clinical …

Introduction: Statins remain among the most frequently prescribed drugs and constitute a
cornerstone in the prevention of cardiovascular disease. However, muscle symptoms are …

The GALAXY Program is a series of clinical studies investigating the efficacy and tolerability
of rosuvastatin in line with the hypothesis that the statin with the greatest efficacy for …

Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination
Products Containing a Statin Page 1 Drug Class Review HMG-CoA Reductase Inhibitors (Statins) …